132513-29-2

Upstream product

• 38449-59-1 2-(3-hydroxyphenyl)ethylamine hydrobromide 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 100-39-0 benzyl bromide 
• 129150-68-1 N-(t-butoxycarbonyl)-2-(3-hydroxyphenyl)-ethylamine 
• 588-05-6 m-tyramine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 51061-22-4 2-(3-benzyloxyphenyl)ethylamine 
• 29973-97-5 2-(3-benzyloxyphenyl)ethyl amine hydrochloride 
• 621-54-5 3-(3-hydroxyphenyl)-propanoic acid 
• 57668-34-5 3-(3-(benzyloxy)phenyl)propanoic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 29973-97-5 2-(3-benzyloxyphenyl)ethyl amine hydrochloride 
• 1415684-09-1 (2S,3R,3aS,12bR)-1,2,3,3a,4,5,7,8-octahydro-10-benzyloxy-2-methyl-3-nitromethyl-5-oxo-cyclopenta[2,3]pyrrolo[2,1-a]isoquinoline 
• 1415684-10-4 (2S,3R,3aS,12bR)-1,2,3,3a,4,5,7,8-octahydro-10-benzyloxy-2-methyl-5-oxo-cyclopenta[2,3]pyrrolo[2,1-a]isoquinoline-3-carboxylic acid 
• 1415684-11-5 methyl ester (2S,3R,3aS,12bR)-1,2,3,3a,4,5,7,8-octahydro-10-benzyloxy-2-methyl-5-oxo-cyclopenta[2,3]pyrrolo[2,1-a]isoquinoline-3-carboxylic acid 
• 1092977-06-4 NW-3509 
• 1092977-45-1 2-(2-(3-butoxyphenyl)-N-tert-butoxycarbonylethylamino)-N,N-dimethylthioacetamide 
• 1092977-08-6 2-(2-(3-butoxyphenyl)-N-tert-butoxycarbonylethylamino)-N,N-dimethylacetamide 
• 1092977-28-0 2-(2-(3-butoxyphenyl)-N-tert-butoxycarbonylethylamino)-N,N-dimethylpropanamide 
• 1092977-07-5 2-(3-butoxyphenyl)-N-tert-butoxycarbonylethylamine 
• 129150-68-1 N-(t-butoxycarbonyl)-2-(3-hydroxyphenyl)-ethylamine 
• 1443828-02-1 6-(benzyloxy)-1-((4-methoxyphenoxy)methyl)-1,2,3,4-tetrahydroisoquinoline 
• 1443828-18-9 (6-(benzyloxy)-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)(3-bromophenyl)methanone 
• 1443828-17-8 (6-(benzyloxy)-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)(3-chlorophenyl)methanone 
• 1443828-16-7 (6-(benzyloxy)-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)(phenyl)methanone 

Relevant academic research and scientific papers

NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Synthesis and structure activity relationship of tetrahydroisoquinoline- based potentiators of GluN2C and GluN2D containing N-Methyl-D-aspartate receptors

We describe here the synthesis and evaluation of a series of tetrahydroisoquinolines that show subunit-selective potentiation of NMDA receptors containing the GluN2C or GluN2D subunits. Bischler-Napieralski conditions were employed in the key step for the

Diverse alkaloid-like structures from a common building block

A wealth of unique enantiopure polycyclic alkaloid-like scaffolds can be prepared on a multigram scale in only a few steps from a common, commercially available intermediate. The attached nitromethyl group can then be used to construct highly diverse func

SYNTHESIS OF POLYCYCLIC ALKALOIDS

Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused

SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologi

DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR

The present invention provides a compound of formula (I): wherein: ? R1 is a group selected from -CH2OH,-NH(CO)H and ? R2 is a hydrogen atom; or ? R1together with R2 form the group -NH-C(O)-CH=CH-, wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R1and the carbon atom is bound to the carbon atom in the phenyl ring holding R2 ? R3a and R3bare independently selected from the group consisting of hydrogen atoms and C1-4alkyl groups, ? n represents an integer from 1 to 3; ? Ad represents 1-adamantyl or 2-adamantyl group, or a pharmaceutically-acceptable salt or solvate or stereoisomer thereof.

SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS

Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) wherein X, Y, Z, R, R1, R2, R3, R'3, R4, R5, R6, R7 have the meanings defined in the specifi

2 -PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS

2-Phenylethylamino substituted carboxamide derivatives of formula (I); wherein J, W, R, R0 R1, R2, R3, and R4 have the meanings as defined in the specification and pharmaceutically acceptable salts th

Total Synthesis of L,L-Isodityrosine and Isodityrosine-Derived Agents: K-13, OF4949-III, and OF4949-IV

Full details of the development of reaction conditions for implementation of an activated Ullmann condensation reaction that may be conducted without amino acid racemization and that have proven suitable for incorporation of the selectively protected cate